Sodium Channels, Carbemazepine and Osteoarthritis Progression

Save

A study published in Nature suggests that therapies affecting sodium channels could be employed to treat osteoarthritis.

2023 Rheumatology Year in Review

Save

Dr. Jack Cush reviews highlights, advances and hot topics in rheumatology from 2023 and the RheumNow website.  

2023 was a year of growth and new horizons while returning to operational and practice standards (in care and education) established before the pandemic.  

Drug-Induced Dermatomyositis

Save

A JAMA Dermatology systematic review of drug-induced dermatomyositis (DM) found the most commonly implicated agents include hydroxyurea, immune checkpoint inhibitors, statins and lipid-lowering agents, penicillamine, and tumor necrosis factor inhibitors.

2023 Rheumatology Year in Review

Save

Here is my top 10 list (in no particular order) of 2023 advances, game-changers, and developments that changed, or will soon change, rheumatologic practices.

Florida Approves Import of Drugs from Canada

Save

Last Friday, the Food and Drug Administration (FDA) approved Florida’s plan to import certain prescription drugs directly from Canada.  Florida is the first time a state to undertake this pathway to save money.

New Year's Resolutions (1.5.2024)

Save

Dr. Jack Cush imparts his new New Year's Resolutions for 2024 and also reviews the news and journal reports from the past week on RheumNow.com.

Best of 2023: Treatment and Management of Neuropsychiatric Lupus

Save

At the 2023 ACR State of the Art conference in Orlando, Florida, Dr. Michelle Petri reviewed the treatment and management of neuropsychiatric lupus. Dr. Petri, a lupus expert from Johns Hopkins Rheumatology, reviewed the latest clinical and animal model studies that offer hope in treatment and gave wide-ranging pearls on a variety of issues that can be faced in this disorder. 

Best of 2023: Does Biologic Treatment in Psoriasis Reduce the Risk of Psoriatic Arthritis?

Save

Retrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.

Best of 2023: Cost-Effective Use of Biological and Targeted Synthetic DMARDs

Save

An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis).